Artwork

Indhold leveret af Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

173 - Balancing Access and Safety: The FDA's Prescription Drug Risk Mitigation Strategy (REMS)

42:08
 
Del
 

Manage episode 381482071 series 70056
Indhold leveret af Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

In this episode, we will discuss the definition of REMS (Risk Evaluation and Mitigation Strategies), why they exist, the role of FDA in administering REMS, types and examples of REMS, and how they impact pharmacy practice.

Key Concepts

  1. The REMS (Risk Evaluation and Mitigation Strategies) program was developed in 2007 as part of the FDA’s drug risk management strategies designed to balance risk and benefits of certain drugs.
  2. Elements of REMS vary depending on the drug, but commonly include medication guides, communication plans, and other elements to assure safe use.
  3. REMS can require patients, providers, and pharmacies to take certain actions including training, registration, enrollment, safety monitoring, documentation of safety concerns, and follow prescribing and dispensing regulations.
  4. The FDA captures and assesses data on a regular basis to make changes in the REMS program. It also has authority to enforce compliance and take punitive actions against non-compliant parties.

References

  continue reading

199 episoder

Artwork
iconDel
 
Manage episode 381482071 series 70056
Indhold leveret af Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

In this episode, we will discuss the definition of REMS (Risk Evaluation and Mitigation Strategies), why they exist, the role of FDA in administering REMS, types and examples of REMS, and how they impact pharmacy practice.

Key Concepts

  1. The REMS (Risk Evaluation and Mitigation Strategies) program was developed in 2007 as part of the FDA’s drug risk management strategies designed to balance risk and benefits of certain drugs.
  2. Elements of REMS vary depending on the drug, but commonly include medication guides, communication plans, and other elements to assure safe use.
  3. REMS can require patients, providers, and pharmacies to take certain actions including training, registration, enrollment, safety monitoring, documentation of safety concerns, and follow prescribing and dispensing regulations.
  4. The FDA captures and assesses data on a regular basis to make changes in the REMS program. It also has authority to enforce compliance and take punitive actions against non-compliant parties.

References

  continue reading

199 episoder

Todos los episodios

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning